Skip to main content
رجوع
Watch Compare

Entera Bio Ltd.

جودة البيانات: 83%
مُدرج أيضًا باسم ENTX Nasdaq
ENTXW
Nasdaq Manufacturing Chemicals

Quick Summary

النقاط الرئيسية

Revenue declined -47.92% annually over 5 years
Negative free cash flow of -7.48 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 28.88%
Capital intensive — 254.76% of revenue goes to capex

النمو

Revenue Growth (5Y)
-47.92%
أقل من متوسط القطاع (9.35%)
Revenue (1Y)-76.80%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-70.42%
أقل من متوسط القطاع (-51.02%)
ROIC-54.12%
Net Margin-27235.71%
Op. Margin-27450.00%

الأمان

Debt / Equity
N/A
Current Ratio10.83
Interest CoverageN/A

التقييم

P/E Ratio
N/A
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (44 نظير)
المقياس السهم وسيط القطاع
P/E — -2.0
P/B — 5.1
ROE % -70.4 -51.0
Net Margin % -27235.7 -150.2
Rev Growth 5Y % -47.9 9.3
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -76.80% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -47.92% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 42,000.0 Net Income (TTM) -11.44 M
ROE -70.42% ROA -61.71%
Gross Margin 0.00% Operating Margin -27450.00%
Net Margin -27235.71% Free Cash Flow (TTM) -7.48 M
ROIC -54.12% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 10.83
Interest Coverage N/A Asset Turnover 0.00
Working Capital 15.44 M Tangible Book Value 15.23 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio N/A Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield N/A
Market Cap N/A Enterprise Value N/A
Per Share
EPS (Diluted TTM) 0.25 Revenue / Share N/A
FCF / Share N/A OCF / Share N/A
EPS CAGR (1Y) 0.00% EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 254.76% FCF Conversion 65.36%
SBC-Adj. FCF -10.45 M Growth Momentum -28.88

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 42,000.0 181,000.0 0.0 134,000.0 571,000.0
Net Income -11.44 M -9.54 M -8.89 M -13.07 M -12.19 M
EPS (Diluted) 0.25 0.25 0.31 0.45 —
Gross Profit 0.0 9,000.0 0.0 33,000.0 198,000.0
Operating Income -11.53 M -9.59 M -8.89 M -13.02 M -12.22 M
EBITDA — — — — —
R&D Expenses 6.00 M 4.50 M 4.51 M 5.85 M 6.77 M
SG&A Expenses 398,000.0 — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax 0.0 14,000.0 29,000.0 137,000.0 -59,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 15.99 M 9.39 M 11.77 M 13.13 M 25.99 M
Total Liabilities 2.89 M 1.31 M 1.38 M 1.37 M 3.42 M
Shareholders' Equity 13.10 M 8.08 M 10.39 M 11.75 M 22.57 M
Total Debt — — — — —
Cash & Equivalents 7.11 M 8.66 M 11.02 M 12.31 M 24.89 M
Current Assets 15.30 M 8.97 M 11.26 M 12.85 M 25.33 M
Current Liabilities 2.20 M 1.18 M 1.09 M 1.34 M 3.16 M